Tetryzoline Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

DRUG NAME: Tetryzoline

Therapeutic Class: Sympathomimetic (Decongestant)
Subclass: Alpha-adrenergic agonist
Speciality: Ophthalmology

Schedule (India): Not scheduled (OTC for ophthalmic use)
Route(s): Ophthalmic, Nasal (topical use only)
Formulations Available in India:
• Ophthalmic drops: 0.05% w/v
• Nasal drops: 0.05% w/v

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Allergic or Non-infective Conjunctival Hyperaemia (Ophthalmic use)

Parameter	Recommendation
Starting dose	1–2 drops in each affected eye
Titration	Not applicable
Usual maintenance dose	1–2 drops up to 4 times daily
Maximum dose	4 applications per day
Maximum duration	3–5 days (short-term use only)

Clinical Notes:
• Not recommended in children <6 years without specialist input
• Avoid contact lens use immediately after instillation — wait at least 15 minutes
• Prolonged use beyond 5 days may cause rebound hyperaemia
• For symptomatic relief only; does not treat underlying cause

▶ Nasal Congestion (associated with rhinitis; Nasal use)

Parameter	Recommendation
Starting dose	1–2 drops per nostril
Titration	Not applicable
Usual maintenance dose	1–2 drops per nostril up to 4 times daily
Maximum dose	4 applications per day
Maximum duration	Not more than 5 consecutive days

Clinical Notes:
• Prolonged use causes rhinitis medicamentosa (rebound congestion)
• Restrict to short-term symptomatic relief only
• Mostly limited to paediatric ENT use or combination drops in Indian practice

Secondary Indications — Adults (Off-label, if any)

▶ Epistaxis Adjunct (topical vasoconstriction before nasal packing) — OFF-LABEL

Parameter	Recommendation
Starting dose	Few drops applied on cotton pledget to bleeding point
Titration	Not applicable
Usual maintenance dose	Single application during procedure
Maximum dose	Single use per procedure
Duration	Single-use during procedure only

• Specialist only
• Evidence basis: Indian ENT practitioner use; limited formal trial evidence

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

▶ Ophthalmic Use — Conjunctival Redness (≥6 years only)

Age Group	Dose	Frequency	Maximum Duration
≥6 years	1 drop in affected eye	Up to 4 times daily	3 days

Clinical Notes:
• Not recommended in children <6 years without ophthalmology specialist supervision
• Risk of systemic absorption with potential CNS effects in younger children

▶ Nasal Use — Paediatric Rhinitis (≥2 years only)

Age Group	Dose	Frequency	Maximum Duration
2–6 years	1 drop per nostril	2–3 times daily	3 days
>6 years	1–2 drops per nostril	2–3 times daily	5 days

Safety Monitoring:
• Observe for lethargy, hypotonia, CNS depression, especially in younger children
• Monitor for drowsiness, irritability, changes in behaviour
• Discontinue immediately if systemic effects observed

Secondary Indications — Paediatric Doses (Off-label, if any)

Not applicable — No established paediatric off-label indications in Indian practice.

Clear statement: Not recommended below 2 years (nasal use) or below 6 years (ophthalmic use) due to significant CNS and cardiorespiratory risks from systemic absorption.

RENAL ADJUSTMENT

No dose adjustment required — minimal systemic absorption expected with proper topical use.

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required
Moderate impairment	No dose adjustment required
Severe impairment	No dose adjustment required

Negligible hepatic metabolism with therapeutic topical use.

CONTRAINDICATIONS

• Known hypersensitivity to tetryzoline or any formulation component
• Narrow-angle glaucoma (ophthalmic use)
• Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
• Children <2 years (nasal use)
• Children <6 years (ophthalmic use) without specialist supervision
• Severe hypertension (nasal use)
• Severe coronary artery disease (nasal use)

CAUTIONS

• Cardiovascular disease — risk of systemic sympathomimetic effects
• Hyperthyroidism — may exacerbate symptoms
• Diabetes mellitus — may affect glucose control
• Elderly patients — increased sensitivity to adrenergic effects
• Prolonged use — risk of rebound congestion (both nasal and ocular)
• Prostatic hypertrophy
• Avoid touching applicator tip to eye or nose to prevent contamination
• Concurrent use of other sympathomimetic agents

PREGNANCY

Consideration	Recommendation
Overall safety	Limited human data; use only if clearly necessary
Risk	Potential systemic vasoconstriction with high doses or prolonged use
When it may be used	Short-term use if benefits outweigh risks; avoid prolonged use
Preferred alternatives	Preservative-free lubricant eye drops for conjunctival irritation; saline nasal drops for congestion
Monitoring	Maternal blood pressure if repeated dosing required

LACTATION

Consideration	Recommendation
Compatibility	Likely compatible with ophthalmic use due to minimal systemic absorption
Drug levels in milk	Expected to be low with proper topical use
Preferred alternatives	Saline nasal drops; preservative-free lubricant eye drops
Infant monitoring	Drowsiness, feeding difficulties if prolonged maternal use or high doses

• Nasal use: Use with caution; consider alternatives

ELDERLY

Consideration	Recommendation
Starting dose	Lowest effective dose (1 drop)
Titration	Not applicable; use shortest duration possible
Risks	Increased sensitivity to systemic adrenergic effects (hypertension, tachycardia, CNS stimulation)
Monitoring	Blood pressure, cognition, especially with nasal route

• Avoid long-term use
• Maximum duration: 3–5 days

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect / Mechanism	Recommendation
Monoamine oxidase inhibitors (MAOIs)	Risk of hypertensive crisis due to potentiation of sympathomimetic effects	Contraindicated — avoid within 14 days of MAOI use
Tricyclic antidepressants (e.g., amitriptyline, imipramine)	Enhanced sympathomimetic effect; risk of hypertension, arrhythmias	Avoid or monitor closely
Other sympathomimetics (phenylephrine, pseudoephedrine)	Additive cardiovascular effects	Avoid concurrent use

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect / Mechanism	Recommendation
Beta-blockers	May mask mutual effects on heart rate and blood pressure	Monitor blood pressure and heart rate
Antihypertensives	May reduce antihypertensive efficacy	Monitor blood pressure
CNS depressants	May potentiate sedative effects in children/infants if systemic absorption occurs	Avoid concurrent use in paediatric patients
Other topical ophthalmic/nasal adrenergics	Additive vasoconstriction	Avoid using multiple agents together

COMMON ADVERSE EFFECTS

Ophthalmic use:
• Transient stinging or burning on instillation
• Eye irritation
• Blurred vision (transient)
• Rebound hyperaemia after prolonged use

Nasal use:
• Local dryness
• Burning sensation
• Sneezing
• Rebound congestion after prolonged use
• Headache

SERIOUS ADVERSE EFFECTS

Adverse Effect	Clinical Note
Systemic absorption in children	Bradycardia, CNS depression, hypotonia, respiratory depression, coma — requires immediate discontinuation and supportive care
Acute angle-closure glaucoma	In predisposed patients (ophthalmic use); requires emergency ophthalmology referral
Hypertensive episodes	In susceptible individuals; discontinue immediately
Cardiac arrhythmias	With significant systemic absorption; more common in elderly or cardiovascular disease patients

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Assess for predisposing conditions (glaucoma, cardiovascular disease, hypertension)
During use (≥3 days)	Monitor for rebound congestion or hyperaemia
Children	Monitor for sedation, drowsiness, lethargy, irritability, hypotonia
Long-term	Not recommended; monitor and reassess if use exceeds 5 days

BRANDS AVAILABLE IN INDIA

Ophthalmic preparations:
• Visine (J&J/Alcon)
• Tizine Eye Drops

Nasal preparations:
• Nazol Nasal Drops

Fixed-dose combinations (commonly available):
• Various FDCs with antihistamines (e.g., pheniramine) or antibacterials available

Note: Many brands in India are part of FDCs with antiallergic agents or antibacterials

PRICE RANGE (INR)

• Ophthalmic drops (5 mL): ₹5–₹15 per bottle
• Nasal drops (10 mL): ₹10–₹25 per bottle
• Not included in NLEM
• Not under NPPA price control
• Available OTC in most pharmacies

CLINICAL PEARLS

• Do not prescribe for more than 5 days — risk of rebound vasodilation (rhinitis medicamentosa or rebound hyperaemia) significantly increases with prolonged use
• Exercise extreme caution when using nasal drops in young children — systemic absorption can cause lethargy, CNS depression, and even coma
• Always assess for narrow-angle glaucoma before prescribing ophthalmic tetryzoline
• Ensure patient or caregiver understands not to exceed recommended dosing frequency
• Clear labelling and education needed to prevent accidental confusion between ophthalmic and nasal preparations
• For chronic red eye or nasal congestion, investigate underlying cause rather than continuing decongestant therapy

VERSION

RxIndia v1.0 — 19 Feb 2026

REFERENCES

• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• AIIMS Paediatric and ENT Protocols
• API Textbook of Medicine
• IAP Textbook of Paediatrics
• Indian ENT specialist hospital practices

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.